Deproteinized Calf Blood Eye Drops Stabilization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current ophthalmic preparations of deproteinized calf blood extract, particularly eye drops, face stability issues when containing Tween-80, necessitating the development of a stable and clinically suitable formulation.
Innovation Solution
The formulation of eye drops incorporating a therapeutically effective amount of deproteinized calf blood extract with chitosan oligosaccharide and water, along with optional bacteriostatic agents, pH regulators, osmotic regulators, and viscosity regulators, enhances stability and safety for clinical application.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Tween-80 is used as a stabilizer in eye drops containing deproteinized calf blood extract, then the formulation can be prepared, but the stability is insufficient and the preparation is unsuitable for clinical application
Solution Approach 1:
The patent replaces Tween-80 with chitosan oligosaccharide as an intermediary substance to stabilize the deproteinized calf blood extract. Chitosan oligosaccharide serves as a more suitable stabilizer that maintains the extract's activity while ensuring clinical applicability, resolving the contradiction between formulation preparation and stability/suitability for clinical use.
Solution Approach 2:
The patent changes the chemical parameter of the stabilizer from Tween-80 (a nonionic surfactant) to chitosan oligosaccharide (a polysaccharide derivative). This parameter change in the stabilizer's molecular structure and chemical properties leads to improved stability and suitability for ophthalmic application while maintaining the extract's therapeutic effects.
2Reliability
If deproteinized calf blood extract is used to treat corneal and conjunctival disorders, then cellular energy metabolism is improved and tissue repair is promoted, but the formulation must achieve adequate stability for clinical use
Solution Approach 1:
Chitosan oligosaccharide acts as an intermediary stabilizer that facilitates the formulation of deproteinized calf blood extract for clinical use. It mediates between the extract's instability and the requirements for clinical formulation, enabling adequate stability while maintaining the therapeutic properties for treating corneal and conjunctival disorders.
Solution Approach 2:
The patent creates a composite formulation combining deproteinized calf blood extract with chitosan oligosaccharide. This composite material approach integrates the therapeutic extract with a stabilizing polysaccharide matrix, achieving both the biological activity needed for tissue repair and the physical stability required for clinical formulation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The eye drops demonstrate improved stability and safety, maintaining effective cellular energy promotion and tissue repair properties, suitable for treating corneal and conjunctival disorders without causing irritation or toxicity.
Implementation Method 1
the stability of the deproteinized calf blood extract can be effectively increased by using a chitosan oligosaccharide
Implementation Method 2
The deproteinized calf blood extract is able to prompt the uptake and utilization of glucose and oxygen in cell mitochondria (independent of insulin) at the cell level, allow the increased ATP synthesis, elevated cell energy
Implementation Method 3
improve microcirculation, activate proliferation of tissue cells, prompt repair of damaged tissue cells
Data Source
AI summary
The present invention provides an eye drops, containing an therapeutically effective amount of the deproteinized calf blood extract, chitosan oligosaccharide, and water. The eye drops of the present invention is stable, and can be used for the treatment of pathological changes of cornea and conjunctiva as well as xerophthalmia.